GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Immunocore Holdings plc
Immunocore is a biotech company that has developed a unique platform for creating T-cell receptor-based drugs. Its stock price reflects the commercial success of its first drug for the treatment of a rare eye cancer and the potential of its scientific platform.
Share prices of companies in the market segment - Oncology immuno-therapy
Immunocore is a biotech company that has developed a unique platform for creating T-cell receptors for the treatment of cancer and viral diseases. We classify it as part of the Oncology Immunotherapy sector, and the chart below reflects the dynamics of this cutting-edge field.
Broad Market Index - GURU.Markets
Immunocore is a British biotech company that has developed a novel platform for creating bispecific T-cell receptors for the treatment of cancer and other diseases. It is a component of the GURU.Markets index. The chart below shows the US market. See how Immunocore shares compare to the US market trend.
Change in the price of a company, segment, and market as a whole per day
IMCR - Daily change in the company's share price Immunocore Holdings plc
The volatility of Immunocore, a biopharmaceutical company, is measured by change_co. It reflects its sensitivity to news about the clinical trials of its oncology drugs. This metric is important for formulas on System.GURU.Markets for analyzing risks and opportunities in the immunotherapy sector.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Immunocore Holdings plc is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IMCR's performance, which depends on the clinical trial results of its immunotherapy platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Immunocore is a biopharmaceutical company pioneering the development of a new class of T-cell receptors for cancer treatment. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this field, helping to assess the risks and dynamics of Immunocore's stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Immunocore Holdings plc
Immunocore is a biotech company that has developed a unique platform for engineering T-cell receptors for cancer treatment. Its year-over-year performance reflects the commercial success of its first drug and investors' confidence in the potential of its scientific platform.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immunocore Holdings plc is a biotech company pioneering the development of a new class of drugs (TCR-based therapies) for the treatment of cancer. The approval of its first drug was a breakthrough. The chart will show how the market views the commercial potential of its unique platform and its progression to commercialization.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immunocore is a biopharmaceutical company whose stock performance is driven by sales success of its immunotherapeutic drugs and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Immunocore Holdings plc
The performance of Immunocore, a biopharmaceutical company, depends on its unique platform. The monthly fluctuations on the chart reflect sales data for its first approved drug for eye cancer, as well as news on clinical trials of other candidates, demonstrating the potential of its technology.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immunocore is a biotech company that has developed a new class of T-cell receptor-based drugs for the treatment of cancer and infectious diseases. This represents a breakthrough in immunotherapy. The chart below shows the overall dynamics of the biotech sector, reflecting the high investor interest in innovative approaches to fighting cancer.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immunocore is a biotech company developing innovative cancer treatments. Like other companies in the sector, its stock is rooted in the world of science and medicine. Its performance is determined by the successful commercialization of its first drug and news from its laboratories, making it independent of overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Immunocore Holdings plc
The weekly performance of Immunocore, a biopharmaceutical company developing a new class of drugs for the treatment of oncology, reflects hopes for a breakthrough in the fight against cancer. The stock price is highly sensitive to the results of clinical trials of its innovative platform.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immuno-oncology is the cutting edge of cancer treatment. The weekly performance of the entire sector depends on clinical trial data from new classes of drugs. The chart illustrates this highly volatile backdrop, against which Immunocore is advancing its unique platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Immunocore is a biotech company developing a new class of drugs (TCR) for the treatment of cancer and other diseases. Shares of such innovative companies often move independently of the market. This chart will help you understand: does Immunocore live in its own world of clinical trials, or does the overall market environment influence its stock price?
Market capitalization of the company, segment and market as a whole
IMCR - Market capitalization of the company Immunocore Holdings plc
Immunocore's market capitalization chart tells the story of a scientific breakthrough in cancer immunotherapy using novel bispecific T-cell receptor technology. Its growth reflects the commercial success of its first approved drug. Its dynamics reflect the market's assessment of the entire platform's potential for developing new drugs against oncological and infectious diseases.
IMCR - Share of the company's market capitalization Immunocore Holdings plc within the market segment - Oncology immuno-therapy
Immunocore is a biotech company that has developed a new platform for creating T-cell receptor-based drugs for the treatment of cancer and other diseases. Its market share reflects the success of its first drug. The chart shows the market share of this innovator, whose technology is opening new horizons in immunotherapy.
Market capitalization of the market segment - Oncology immuno-therapy
Immunocore is a biotech company that has developed a new class of drugs (bispecific T-cell receptors) for the treatment of cancer. The graph below shows the market capitalization of the oncology sector. Its rapid growth reflects scientific progress, and Immunocore's breakthrough technology is part of this revolution.
Market capitalization of all companies included in a broad market index - GURU.Markets
Immunocore is a biotech company that has developed a new platform for cancer immunotherapy based on T-cell receptors. Its market capitalization is based on the potential of this breakthrough technology. The chart below shows the economic weight of companies developing new classes of drugs.
Book value capitalization of the company, segment and market as a whole
IMCR - Book value capitalization of the company Immunocore Holdings plc
Immunocore's assets include its research laboratories, patents for a unique T-cell receptor platform, and capital for developing innovative cancer treatments. This is a tangible, science-intensive foundation for the immuno-oncology of the future. How has this biotech asset grown? The chart below clearly shows its development dynamics.
IMCR - Share of the company's book capitalization Immunocore Holdings plc within the market segment - Oncology immuno-therapy
Immunocore is developing a new class of immunotherapeutic drugs in its cutting-edge laboratories and manufacturing facilities. The chart shows the share of these high-tech assets in the pharmaceutical sector, reflecting the physical foundation of its unique technological platform.
Market segment balance sheet capitalization - Oncology immuno-therapy
Immuno-oncology is one of the most knowledge-intensive fields. The BCap_Seg graph for biotech is low compared to industry. Immunocore operates in this environment, where its assets are not factories, but a unique platform for creating T-cell receptors. This is capital intensity of intelligence, not concrete.
Book value of all companies included in the broad market index - GURU.Markets
Immunocore's balance sheet is not comprised of traditional chemical plants, but rather high-tech bioreactors and laboratories for the production of immunotherapeutic drugs. Its value reflects the capital invested in a unique physical infrastructure capable of creating complex protein molecules to fight cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Immunocore Holdings plc
Immunocore is a biotech company developing a new class of drugs (TCR bispecifics) for cancer treatment. Its balance sheet doesn't reflect its scientific platform or development potential. The MvsBCap chart is a bet on a revolution in immuno-oncology. Its high value and volatility demonstrate both the enormous promise and the risks inherent in cutting-edge science.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Immunocore Holdings is a biotech company developing a new class of drugs based on T-cell receptors. Its value is determined solely by the potential of its scientific platform. This chart reflects investors' high expectations for future breakthroughs, not the current value of its assets.
Market to book capitalization ratio for the market as a whole
Immunocore Holdings is a pioneer in developing a new class of T-cell receptor-based drugs for the treatment of oncology. The company's value lies solely in its scientific platform and the potential of its future drugs. This chart illustrates the enormous premium investors pay for revolutionary medical technologies that have the potential to change the treatment paradigm.
Debts of the company, segment and market as a whole
IMCR - Company debts Immunocore Holdings plc
Immunocore, a biopharmaceutical company specializing in cancer immunotherapy, is raising capital to fund its cutting-edge research and clinical programs. Developing a new cancer treatment platform is a lengthy and costly process. This chart shows how the company is investing in science that could transform cancer treatment.
Market segment debts - Oncology immuno-therapy
Immunocore Holdings is a biotechnology company developing a new class of drugs (TCR-bispecific immunotherapies) for the treatment of oncology and infectious diseases. Funding breakthrough research requires significant capital. The chart shows how Immunocore uses financial instruments to advance its unique platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Immunocore Holdings plc
Immunocore Holdings is developing a new class of drugs—T-cell receptor-based immunotherapy. This chart shows how the company is funding its cutting-edge research. For a biotech company with a revolutionary but not yet fully commercialized platform, debt is a bet on the future. Its size reflects both the potential and the enormous risks.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Immunocore Holdings develops innovative immunotherapeutic drugs for cancer. For the biotech sector in which the company operates, this chart shows the general willingness of investors to fund lengthy and expensive clinical trials. This allows one to evaluate the company's financial strategy in the context of the high-risk scientific race.
Debt to book value of all companies in the market
Immunocore Holdings is a biotech company operating at the cutting edge of science. This chart reflects the overall risk appetite in the economy. For a company burning capital for future discoveries, it helps understand how its risky funding model compares to the overall market conditions and investors' willingness to wait.
P/E of the company, segment and market as a whole
P/E - Immunocore Holdings plc
For Immunocore Holdings, a company developing innovative immunotherapeutic drugs, this chart reflects faith in its scientific platform. High values indicate that investors are assessing not current revenue, but the potential for future blockbusters that could change approaches to cancer treatment.
P/E of the market segment - Oncology immuno-therapy
This chart shows the average price-to-earnings ratio for the immuno-oncology sector, where Immunocore is a pioneer. The industry is valued at a significant premium for its scientific potential. The chart illustrates the overall level of investor expectations, providing context for understanding how Immunocore's unique technology is valued even compared to other biotech companies.
P/E of the market as a whole
Immunocore Holdings is a biotech company developing a new class of T-cell receptor-based drugs for the treatment of oncology and infectious diseases. This breakthrough technology is a key driver of the market's investment climate. This overall investment climate chart provides insight into the market's confidence in the potential of Immunocore's platform, valuing it higher than companies with more traditional approaches.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Immunocore Holdings plc
Immunocore Holdings is a biotechnology company developing a new class of drugs (TCR-bispecific immunotherapies) for the treatment of oncology. The chart reflects investor expectations regarding the commercial success of its first drug and the potential of the entire platform. Future revenues depend on the results of clinical trials.
%20P%2FE%20Immunocore%20Holdings%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Immunocore-Holdings-plc&v=1772688642194 "Chart of the company's future (projected) P/E Immunocore Holdings plc")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Immunocore Holdings is a biotech company developing a new class of T-cell receptor-based drugs for the treatment of oncology and infectious diseases. This chart reflects expectations for future profits in the sector. It helps understand the extent to which investors believe in the breakthrough potential of Immunocore's platform and the future success of its drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772688642205 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Immunocore Holdings is a biotech company developing a new class of T-cell receptor-based drugs for the treatment of cancer and infectious diseases. Its valuation depends on the success of clinical trials. This market sentiment chart shows how much investors are prepared to bear the risk associated with investing in cutting-edge science.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772688642235 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Immunocore Holdings plc
Immunocore Holdings is a biotech company that has developed a novel platform for creating T-cell receptor-based drugs for the treatment of oncology and infectious diseases. Its profitability depends on the successful commercialization of its first drug and the development of its pipeline. This chart shows the innovative company's financial path from research to sales.
Profit of companies in the market segment - Oncology immuno-therapy
Immunocore Holdings is a biotech company developing a new class of T-cell receptor-based drugs for the treatment of cancer and infectious diseases. This is a cutting-edge field of science. This chart illustrates the overall picture in the immuno-oncology sector, where high investment in research can lead to breakthrough therapies and high profitability.
Overall market profit
Immunocore Holdings is a biotechnology company developing a new class of T-cell receptor-based drugs for the treatment of oncology and infectious diseases. Its prospects depend on scientific breakthroughs and clinical trial results. The overall economic environment, reflected in this chart, has little impact on its development progress or potential.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Immunocore Holdings plc
Immunocore Holdings is a biotechnology company developing a new class of T-cell receptor-based drugs for the treatment of oncology and infectious diseases. Future revenue depends on the success of its innovative platform. This chart reflects analyst expectations regarding the clinical results and commercial potential of Immunocore's products.
%20profit%20of%20the%20company%20Immunocore%20Holdings%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Immunocore-Holdings-plc&v=1772688642281 "Graph of future (projected) profit of the company Immunocore Holdings plc")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Immunocore Holdings is a biotechnology company developing a new class of T-cell receptor-based drugs for the treatment of oncology and infectious diseases. Its success depends on clinical breakthroughs and platform commercialization. This chart shows overall revenue projections for the immuno-oncology sector, helping to assess Immunocore's scientific and commercial potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772688642300 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Immunocore Holdings is a biotechnology company developing a new class of immunotherapeutic drugs for the treatment of oncology and infectious diseases. Its prospects depend on the success of clinical trials. This economic outlook affects the overall investment climate in the biotechnology sector, which influences funding.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772688642331 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Immunocore Holdings plc
Immunocore Holdings is a biotech company developing a new class of drugs (TCR-bispecific immunotherapies) for the treatment of cancer and other diseases. For such an innovative company, revenue from its first approved drug is proof of the platform's viability. The chart demonstrates investor confidence in future blockbusters.
P/S market segment - Oncology immuno-therapy
Immunocore is a biotech company that has developed a new class of T-cell receptor-based drugs for the treatment of oncology and infectious diseases. Their first platform has already proven effective, paving the way for new therapies. This chart shows the average revenue estimate for the immuno-oncology sector, reflecting expectations for Immunocore's innovative platform.
P/S of the market as a whole
Immunocore Holdings is a biotech company developing a new class of immunotherapeutic drugs for the treatment of oncology and infectious diseases. Its TCR platform is groundbreaking. This chart demonstrates that the valuation of such companies is based not on current revenue, but on investor confidence in the scientific platform and the future potential of its drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Immunocore Holdings plc
Immunocore Holdings is a biotechnology company developing a new class of T-cell receptor-based drugs for the treatment of oncology and infectious diseases. Estimating future revenue for such an innovative platform is critical, reflecting investors' confidence in the potential of its technology and the future commercial success of the drugs in development.
%20P%2FS%20Immunocore%20Holdings%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Immunocore-Holdings-plc&v=1772688642383 "The graph of the company's future (projected) P/S Immunocore Holdings plc")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Immunocore Holdings is a biotech company developing a new class of T-cell receptor-based drugs for the treatment of oncology and infectious diseases. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the potential of its unique ImmTAC platform for creating breakthrough treatments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772688642395 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Immunocore Holdings is developing a new class of immunotherapeutic drugs for the treatment of oncology. The company's prospects depend on scientific breakthroughs and regulatory approvals. In the context of the overall revenue forecasts shown in the chart, Immunocore is betting on a revolution in medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772688642397 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Immunocore Holdings plc
This figure reflects the revenue of Immunocore Holdings, a biotechnology company developing a new class of immunotherapeutic drugs for the treatment of oncology and infectious diseases. Revenue is generated from sales of its first commercial product. The growth of this indicator indicates the successful launch of the innovative drug and its acceptance by the medical community.
Sales of companies in the market segment - Oncology immuno-therapy
Immunocore Holdings is a pioneer in developing a new class of drugs, T-cell receptors, for the treatment of oncology and infectious diseases. The company's sales profile, as commercialization progresses, will determine which of its drugs becomes a blockbuster. Currently, its key drug is a treatment for uveal melanoma.
Overall market sales
Immunocore Holdings is a biotech company developing a new class of drugs for the treatment of oncology and infectious diseases. Its value and prospects are determined by the success of clinical trials. This overall market performance chart serves only as a backdrop for a company whose fate is decided in laboratories and clinics, not in the consumer market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Immunocore Holdings plc
Immunocore Holdings is a biotechnology company developing a new class of drugs (TCR-bispecific immunotherapies) for the treatment of oncology and infectious diseases. Its future revenue depends on the success of clinical trials and commercialization. This chart reflects analysts' sales forecasts for its first approved drug and the potential for other developments.
%20sales%20of%20the%20company%20Immunocore%20Holdings%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Immunocore-Holdings-plc&v=1772688642568 "Schedule of future (projected) sales of the company Immunocore Holdings plc")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Immunocore Holdings is a biotech company developing a new class of T-cell receptor-based drugs for the treatment of oncology and infections. This chart shows the outlook for the immuno-oncology sector. Is market growth expected due to breakthrough technologies? This helps assess the overall potential of this cutting-edge field of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772688642654 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Immunocore Holdings is a biotechnology company developing a new class of immunotherapeutic drugs for the treatment of oncology and infectious diseases. Its success is determined by scientific breakthroughs and clinical trial results. This chart, reflecting consumer sentiment, is not directly related to the company's fundamental growth drivers.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772688642699 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Immunocore Holdings plc
Immunocore Holdings is a biotech company developing a new class of T-cell receptor-based drugs for the treatment of oncology and infectious diseases. This graph shows its path from research to commercialization. Profitability depends on the success of its innovative platform and the ability to bring to market drugs that transform the treatment of serious diseases.
Market segment marginality - Oncology immuno-therapy
Immunocore Holdings plc is a biotechnology company developing a new class of T-cell receptor-based immunotherapeutics for the treatment of oncology and infectious diseases. This metric reflects the financial position of the company, which boasts a unique scientific platform, whose future profitability depends on the success of its clinical programs and product commercialization.
Market marginality as a whole
Immunocore Holdings, a pioneer in cancer immunotherapy, operates at the forefront of science. Its development requires significant investment in R&D. This total return chart reflects the state of financial markets and investor willingness to finance long-term, risky biotech projects, which is critical to the company's future.
Employees in the company, segment and market as a whole
Number of employees in the company Immunocore Holdings plc
Immunocore Holdings is a biotechnology company developing a new class of drugs (TCR bispecifics) for the treatment of oncology and infectious diseases. Its team of scientists is the driving force behind innovation. This chart shows how the company is expanding its staff to conduct clinical trials and commercialize its first approved drug.
Share of the company's employees Immunocore Holdings plc within the market segment - Oncology immuno-therapy
Immunocore Holdings is developing a new class of T-cell receptor-based immunotherapeutics for the treatment of oncology and infectious diseases. Its team consists primarily of highly qualified scientists and researchers. This graph shows the company's market share, which is an indicator of its scientific potential and the scale of its biotech R&D activities.
Number of employees in the market segment - Oncology immuno-therapy
Immunocore Holdings is a biotech company developing a new class of T-cell receptor-based drugs for the treatment of oncological and infectious diseases. The chart shows employment in the immuno-oncology sector. Exponential growth here speaks to a revolution in cancer treatment, and Immunocore is at the forefront of this breakthrough.
Number of employees in the market as a whole
Immunocore Holdings develops an innovative class of drugs, T-cell receptors, for the treatment of oncology and infectious diseases. The growth of its research team, compared to the overall employment in this chart, is a marker of a breakthrough in immunotherapy. Hiring here reflects successful clinical trials and confidence in the new technology, not the economic cycle.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Immunocore Holdings plc (IMCR)
Immunocore is a biotech company with a unique cancer immunotherapy platform. This chart shows how the market values their scientific breakthrough. With a relatively small team of elite scientists, they have created a product approved for the treatment of a rare cancer. The astronomical market capitalization per employee reflects the value of their platform.
%20of%20the%20company%20Immunocore%20Holdings%20plc%20(IMCR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Immunocore-Holdings-plc-IMCR&v=1772688642850 "Chart of market capitalization per employee (in thousands of dollars) of the company Immunocore Holdings plc (IMCR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Immunocore (IMCR) is a biotech company that has developed a bispecific T-cell receptor (TCR) platform for the treatment of cancer (KIMMTRAK) and infectious diseases. This chart shows the average market capitalization per employee in the sector. It helps assess how much the market values their unique scientific platform (TCR) per scientist.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772688642859 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Immunocore is a biotech company developing a new class of drugs (TCR-bispecific immunotherapies) for cancer treatment. Its value lies in its unique scientific platform. The chart shows an astronomical valuation per employee, as the market believes in the potential of this technology to revolutionize oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772688642884 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Immunocore Holdings plc (IMCR)
Immunocore is a biotech company developing a new class of drugs (TCR) for the treatment of oncology. The company already has an approved drug. This chart shows the transition from R&D costs to commercial revenue. It demonstrates how effectively the sales and marketing team is monetizing the unique scientific platform developed by their scientists.
%20Chart%20Immunocore%20Holdings%20plc%20(IMCR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Immunocore-Holdings-plc-IMCR&v=1772688642907 "Company Profit Per Employee (in thousands of dollars) Chart Immunocore Holdings plc (IMCR)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Immunocore (IMCR) is a biotech R&D company (TCR-based cancer therapy). This chart shows the benchmark for "Immuno-oncology" (R&D). The average profit per employee in this sector (venture R&D) is *negative* (or high if there is one hit). This benchmark reflects the "burning" of cash in the hopes of one or two mega-successes.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772688642951 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Immunocore Holdings is a biotech company developing a new class of drugs (TCR bispecifics) for the treatment of oncology and infectious diseases. They have their first approved drug. This chart shows the transition from R&D losses to profitability. It reflects how well sales of the first drug cover the costs of extensive R&D.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772688642960 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Immunocore Holdings plc (IMCR)
Immunocore Holdings is a biotech company developing a new class of drugs (TCR). This chart shows the financial return on their unique scientific platform. The high revenue per employee after product commercialization reflects the enormous cost of innovation, where a small team of scientists creates a therapy worth billions of dollars.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Immunocore-Holdings-plc-IMCR&v=1772688642972 "Sales chart per company employee Immunocore Holdings plc (IMCR)")
Sales per employee in the market segment - Oncology immuno-therapy
Immunocore Holdings is a biotech company. They are developing a new class of drugs (TCR therapy) for the treatment of oncology and autoimmune diseases. They already have an approved drug. This chart shows the average revenue in the sector. For Immunocore Holdings, this is an indicator of how successfully their innovative platform and R&D team are converting into sales and revenue compared to other biotech companies.
Sales per employee for the market as a whole
Immunocore is a biotech company developing a new class of drugs (TCR) for the treatment of oncology and autoimmune diseases. Their business is focused on cutting-edge science. This metric demonstrates how effectively their R&D platform can create commercially successful drugs that can then generate significant revenue per scientist.
Short shares by company, segment and market as a whole
Shares shorted by company Immunocore Holdings plc (IMCR)
Immunocore (IMCR) is a biotech company developing a new class of drugs (TCR therapy) for the treatment of oncology and infectious diseases. This chart tracks short positions. Bears may doubt the broad potential of this complex technology, fear failures in clinical trials for new indications, or believe the current success of one drug is already priced in.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Immunocore-Holdings-plc-IMCR&v=1772688643041 "Short Shares Chart for the Company Immunocore Holdings plc (IMCR)")
Shares shorted by market segment - Oncology immuno-therapy
Immunocore (IMCR) is a biotech company developing a new class of drugs (TCR bispecifics) for the treatment of oncology. This chart shows the total short position in the immuno-oncology sector. It reflects investor concerns about the high level of competition in this field and the risks of clinical trials of new platforms.
Shares shorted by the overall market
Immunocore (IMCR) is a clinical-stage biotech (oncology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives IMCR of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Immunocore Holdings plc (IMCR)
Immunocore is a biotech company pioneering TCR-based therapies (immuno-oncology). The stock is volatile and dependent on R&D. A price above 70 may reflect positive trial data or FDA approval. Oversold levels (<30) are often associated with research setbacks or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Immunocore-Holdings-plc-IMCR&v=1772688643228 "RSI 14 indicator chart for the company's stock Immunocore Holdings plc (IMCR)")
RSI 14 Market Segment - Oncology immuno-therapy
Immunocore (IMCR) is a biotech company, a pioneer in TCR (T-cell receptor). Their platform "trains" the immune system to attack cancer. RSI_14_Seg for "Oncology" (biotech) reflects the overall sentiment. It helps us understand whether IMCR's volatility reflects their breakthrough platform or general hype in the sector.
RSI 14 for the overall market
Immunocore (IMCR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMCR (Immunocore Holdings plc)
Immunocore Holdings is a biotech company that has developed a novel T-cell receptor (TCR) platform for cancer treatment. Its first drug has been approved for a rare form of eye cancer. This chart shows the average analyst forecast. Their price targets are based on the success of this launch and the potential of their TCR platform for treating other cancers.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMCR-Immunocore-Holdings-plc&v=1772688643276 "A chart showing analyst consensus forecasts for the expected stock price. IMCR (Immunocore Holdings plc)")
The difference between the consensus estimate and the actual stock price IMCR (Immunocore Holdings plc)
Immunocore is a biotech company that has developed a unique bispecific T-cell receptor (TCR) platform. Their first drug (Kimmtrak) was approved for the treatment of a rare eye cancer. This chart shows how confident analysts are that their innovative platform will be able to treat more common cancers.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMCR-Immunocore-Holdings-plc&v=1772688643280 "A chart showing the difference between the consensus forecast and the actual stock price. IMCR (Immunocore Holdings plc)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Immunocore is a biotech company that has developed a new class of immunotherapy—bispecific T-cell receptors (ImmTACs)—for the treatment of cancer and infections. This chart shows analysts' overall expectations for the oncology immunotherapy sector. It reflects whether experts believe this platform has potential beyond ocular melanoma.
Analysts' consensus forecast for the overall market share price
Immunocore is a biotech company that has developed a novel bispecific T-cell receptor (TCR) platform for the treatment of cancer (melanoma) and autoimmune diseases. This chart shows overall market sentiment. For Immunocore, which operates at the forefront of immunotherapy, it's important to understand how overall risk appetite (analyst sentiment) influences funding for its platform. (350)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Immunocore Holdings plc
Immunocore (IMCR) is a biotech company with a unique platform (TCR) for training the immune system. Their technology enables T cells to see and attack previously invisible cancers. This graph represents their R&D bet. It reflects the commercial success of their first drug (Kimmtrak) and the enormous potential of their scientific platform for treating other cold-type tumors.
AKIMA Market Segment Index - Oncology immuno-therapy
Immunocore (IMCR) is a biotech pioneer in new immunotherapy (TCR) technology; the company created the world's first drug (Kimmtrak) for the treatment of a rare eye cancer (uveal melanoma). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does IMCR's breakthrough TCR R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Immunocore is a biotech company pioneering T-cell receptor (TCR) therapy for cancer and infectious diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story with an approved product (Kimmtrak) compares to the overall economic trends affecting biotech.
